Posts by David Cheng, PhD
-
No Incremental Safety Risk Attributable to Anti-TNF Therapy in Older Patients with Ulcerative Colitis
By pooling data from four clinical trials, David Cheng, PhD, Kelly C. Cushing, and Ashwin N. Ananthakrishnan, MBBS, MPH, and colleagues found that ulcerative colitis patients who are ≥60 years old treated with tumor necrosis factor-α antagonists did not exhibit increased risk of serious adverse events attributable to the treatment.
Biography
r. Cheng is an Instructor of Investigation at Mass General and an Instructor in Medicine at HMS. He collaborates with multiple groups at Mass General, including the Division of General Internal Medicine and the Mongan Institute. His collaborative research includes work in cancer, autoimmune diseases, and cardiovascular diseases. His methodological research is in causal inference and data integration. He is particularly interested in developing methods and applications to facilitate comparative effectiveness research and precision medicine using electronic health records data. He received his PhD in Biostatistics from Harvard University in 2018 and also holds an AM in Biostatistics from Harvard and a BA in Economics and Statistics from the University of Chicago.
